Lehdistötiedote

Invitation to audiocast for Devyser’s Q1 report 2026

On Monday April 27 at 11:00 a.m. CET, Devyser Diagnostics AB will host an online presentation of its Q1 2026 report (which will have been published earlier on April 27 at 09:00 a.m. CET).

The presentation will be held in English.

If you wish to participate via webcast please use the link below.
https://devyser-diagnostics.events.inderes.com/q1-report-2026

If you wish to participate via teleconference, please register on the link below. After registration you will be provided phone numbers and a conference ID to access the conference. You can ask questions verbally via the teleconference. https://events.inderes.com/devyser-diagnostics/q1-report-2026/dial-in

Speakers: CEO Jan Wahlström and CFO Sabina Berlin

About Devyser
Devyser is redefining how laboratories approach genetic testing. As your true one-stop shop, we offer streamlined solutions for a wide range of conditions, helping labs overcome complexity, reduce turnaround times, and maximize efficiency. 

Our technologies simplify workflows, minimize hands-on time, and deliver fast, accurate results. Every test is designed to empower labs to do more with less, freeing up resources while supporting better patient outcomes. 

We specialize in diagnostic kits and advanced analysis services for clinical genetics and post-transplantation laboratories - two critical areas where accuracy and speed matter. With customers in 65+ countries, we also operate our own CLIA-certified laboratory, Devyser Genomic Laboratories, in Atlanta and maintain sales offices across Europe and the US. 

Devyser is committed to regulatory excellence under IVDR, ensuring the highest quality standards across our growing product portfolio. 

Founded in 2004 and headquartered in Stockholm, Devyser is listed on the Nasdaq First North Premier Growth Market Stockholm (ticker: DVYSR). Redeye Nordic Growth AB is the company's Certified Adviser.

Discover how we're shaping the future of lab diagnostics at www.devyser.com. 